2026-01-14 - Analysis Report
**Company Overview**
Eli Lilly and Co is a global pharmaceutical company.

**Return Comparison**
The cumulative return of Eli Lilly and Co (LLY) is higher than that of S&P 500 (VOO).

* **Cumulative Return (LLY)**: 280.56%
* **Cumulative Return (VOO)**: 93.94%
* **Divergence**: 186.62% ($233.30 - $46.68)
* **Relative Divergence**: 80.50% ($233.30 - $31.10)

**Alpha, Beta Analysis**
| **Year** | **CAGR** | **MDD** | **Alpha** | **Beta** | **Cap(B)** |
|---------|--------|-------|----------|---------|-----------|
| 2016-2018 | 37.0% | 14.3% | 33.0% | 0.7 | 103.7B |
| 2017-2019 | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020 | 30.0% | 20.9% | 10.0% | 0.7 | 151.4B |
| 2019-2021 | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022 | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023 | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024 | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025 | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

**Recent Stock Price Fluctuations**
* **5-day SMA**: $1,083.01
* **20-day SMA**: $1,071.18
* **60-day SMA**: $996.84
* **Close**: $1,077.19
* **Recent Fluctuation**: Sharp Decline (-0.35% from previous day)

**RSI, PPO Index Indicators**
* **Market Risk Indicator**: 0.70 (High Investment Recommended)
* **RSI**: 50.18
* **PPO**: -0.30
* **Expected Return**: 52.10%

**Recent News & Significant Events**
[2026-01-07] Eli Lilly (LLY) Stock Is Up, What You Need To Know - Yahoo Finance (news.google.com)
[2026-01-09] Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences - Investor's Business Daily (news.google.com)
[2026-01-13] Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St. (news.google.com)
[2026-01-11] This Healthcare Stock Could Be One of the Best Companies to Own in 2026 - The Motley Fool (news.google.com)
[2026-01-09] Stock Quote & Chart | Eli Lilly and Company - Eli Lilly (news.google.com)
[2026-01-09] Eli Lilly vs. Novo Nordisk: Which Is the Best Stock to Buy Today? - Morningstar (news.google.com)

**Analyst Opinions**
* Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 1116.33 / 1500.00 / 770.00

**Recent Earnings Analysis**
| **Date** | **EPS** | **Revenue** |
|---------|--------|-------------|
| 2025-10-30 | 6.22 | $17.60 B$ |
| 2025-08-07 | 6.3 | $15.56 B$ |
| 2025-05-01 | 3.07 | $12.73 B$ |
| 2024-10-30 | 1.08 | $11.44 B$ |
| 2025-10-30 | 1.08 | $11.44 B$ |

**Financial Information - Revenue and Profitability**
| **Quarter** | **Revenue** | **Profit Margin** |
|---------|-------------|-------------------|
| 2025-09-30 | $17.60 B$ | 82.91% |
| 2025-06-30 | $15.56 B$ | 84.27% |
| 2025-03-31 | $12.73 B$ | 82.53% |
| 2024-12-31 | $13.53 B$ | 82.24% |
| 2024-09-30 | $11.44 B$ | 81.02% |

**Financial Information - Capital and Profitability**
| **Quarter** | **Equity** | **ROE** |
|---------|---------|------|
| 2025-09-30 | $23.79 B$ | 23.46% |
| 2025-06-30 | $18.27 B$ | 30.98% |
| 2025-03-31 | $15.76 B$ | 17.50% |
| 2024-12-31 | $14.19 B$ | 31.07% |
| 2024-09-30 | $14.24 B$ | 6.81% |

**Comprehensive Analysis**
The report highlights the impressive cumulative return of 280.56% for Eli Lilly and Co, significantly higher than the S&P 500. The company's financial performance, including revenue and profitability, has been strong, with a profit margin of up to 84.27% and a return on equity (ROE) of up to 30.98% in some quarters. Analyst opinions are positive, with a consensus of "Buy" and a target price of $1,116.33. The recent news and significant events suggest a sharp decline in stock price but also mention the company's plan to acquire Ventyx Biosciences. The risk indicator is medium, suggesting a moderate level of risk associated with the investment. Overall, the company's financial performance and positive analyst opinions make it an attractive investment option.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.